Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - Malta

# **SAFETY DATA SHEET**



TEKNODUR COMBI 3440-05 - All variants

## SECTION 1: Identification of the substance/mixture and of the company/ undertaking

### 1.1 Product identifier

Product name

: TEKNODUR COMBI 3440-05 - All variants

**1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use**: Paint.

#### 1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

#### responsible for this SDS National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

#### 1.4 Emergency telephone number

#### National advisory body/Poison Centre

 Telephone number
 : Malta Competition and Consumer Affairs Authority (MCCAA): +356 2395 2000

## **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Eye Irrit. 2, H319 STOT SE 3, H336 Aquatic Chronic 2, H411

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

ŝ

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Hazard pictograms

| Signal word                      | /arning  |    |
|----------------------------------|--|----|
| Hazard statements                | 226 - Flammable liquid and vapour.<br>319 - Causes serious eye irritation.<br>336 - May cause drowsiness or dizziness.<br>411 - Toxic to aquatic life with long lasting effects.       |    |
| Precautionary statements         |  |    |
| Prevention                       | 280 - Wear eye or face protection.<br>210 - Keep away from heat, hot surfaces, sparks, open flames and other ignitic<br>ources. No smoking.<br>273 - Avoid release to the environment. | วท |
| Response                         | 391 - Collect spillage.  |    |
| Storage                          | 403 + P233 - Store in a well-ventilated place. Keep container tightly closed.  |    |
| Dete of issue (Dete of multiples |  | 40 |

## SECTION 2: Hazards identification

|   | - |   |
|---|---|---|
| Disposal  | : | P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.  |
| Hazardous ingredients   | : | Contains: n-Butyl acetate and 2-Methoxy-1-methylethyl acetate   |
| Supplemental label elements   | : | Contains Maleic anhydride. May produce an allergic reaction.<br>Warning! Hazardous respirable droplets may be formed when sprayed. Do not<br>breathe spray or mist. |
| Annex XVII - Restrictions<br>on the manufacture,<br>placing on the market and<br>use of certain dangerous<br>substances, mixtures and<br>articles | : |   |
| 2.3 Other hazards   |   |   |
| Product meets the criteria<br>for PBT or vPvB according<br>to Regulation (EC) No.<br>1907/2006, Annex XIII  | : | This mixture does not contain any substances that are assessed to be a PBT or a vPvB.   |
| Other hazards which do  | : | None known.   |

Other hazards which do not result in classification

## **SECTION 3: Composition/information on ingredients**

| 3.2 Mixtures  | : Mixture  |                  |   |   |                |
|---|--|------------------|---|---|----------------|
| Product/ingredient name   | Identifiers  | %                | Classification                                      | Specific Conc.<br>Limits, M-factors<br>and ATEs | Туре           |
| titanium dioxide  | REACH #:<br>01-2119489379-17<br>EC: 236-675-5<br>CAS: 13463-67-7                       | ≥10 - ≤25        | Carc. 2, H351<br>(inhalation)                       | -   | [1] [*]        |
| n-Butyl acetate   | REACH #:<br>01-2119485493-29<br>EC: 204-658-1<br>CAS: 123-86-4<br>Index: 607-025-00-1  | ≥10 - ≤25        | Flam. Liq. 3, H226<br>STOT SE 3, H336<br>EUH066     | -   | [1] [2]        |
| 2-Methoxy-1-methylethyl<br>acetate  | REACH #:<br>01-2119475791-29<br>EC: 203-603-9<br>CAS: 108-65-6<br>Index: 607-195-00-7  | ≤10              | Flam. Liq. 3, H226<br>STOT SE 3, H336               | -   | [1] [2]        |
| Trizinc bis(orthophosphate)   | REACH #:<br>01-2119485044-40<br>EC: 231-944-3<br>CAS: 7779-90-0<br>Index: 030-011-00-6 | ≤5               | Aquatic Acute 1, H400<br>Aquatic Chronic 1,<br>H410 | M [Acute] = 1<br>M [Chronic] = 1                | [1]            |
| Phosphoric acid, polymer<br>with 4,4'-<br>(1-methylethylidene)bis<br>[phenol] and 2,2'-[<br>(1-methylethylidene)bis<br>(4,1-phenyleneoxymethylene)]<br>bis[oxir<br>ane] | -  | <3               | Flam. Liq. 3, H226<br>Eye Dam. 1, H318              | -   | [1]            |
| Isobutyl acetate  | REACH #:<br>01-2119488971-22<br>EC: 203-745-1<br>CAS: 110-19-0                         | ≤3               | Flam. Liq. 2, H225<br>STOT SE 3, H336<br>EUH066     | -   | [1] [2]        |
| Date of issue/Date of revision  | :06/10/2023 Dat  | e of previous is | sue : 11/10/2022                                    | Version : 1.0                                   | 01 <b>2/19</b> |
| TEKNODUR COMBI 3440-05  | 5 - All variants   |                  |   | Label No :508                                   | 885            |

|                        | Index: 607-026-00-7   |        |   |  |         |
|------------------------|---|--------|---|--|---------|
| 2-Butoxyethanol        | REACH #:<br>01-2119475108-36<br>EC: 203-905-0<br>CAS: 111-76-2<br>Index: 603-014-00-0 | <1     | Acute Tox. 4, H302<br>Acute Tox. 3, H331<br>Skin Irrit. 2, H315<br>Eye Irrit. 2, H319   | ATE [Oral] = 1200<br>mg/kg<br>ATE [Inhalation<br>(vapours)] = 3 mg/l | [1] [2] |
| Methylisobutylketone   | REACH #:<br>01-2119473980-30<br>EC: 203-550-1<br>CAS: 108-10-1<br>Index: 606-004-00-4 | ≤0.3   | Flam. Liq. 2, H225<br>Acute Tox. 4, H332<br>Eye Irrit. 2, H319<br>Carc. 2, H351<br>STOT SE 3, H336<br>EUH066  | ATE [Inhalation<br>(vapours)] = 11 mg/<br>I                          | [1] [2] |
| propylidynetrimethanol | REACH #:<br>01-2119486799-10<br>EC: 201-074-9<br>CAS: 77-99-6                         | ≤0.3   | Repr. 2, H361fd   | -  | [1]     |
| Maleic anhydride       | REACH #:<br>01-2119472428-31<br>EC: 203-571-6<br>CAS: 108-31-6<br>Index: 607-096-00-9 | <0.001 | Acute Tox. 4, H302<br>Skin Corr. 1B, H314<br>Eye Dam. 1, H318<br>Resp. Sens. 1, H334<br>Skin Sens. 1A, H317<br>STOT RE 1, H372<br>(respiratory system)<br>(inhalation)<br>EUH071<br>See Section 16 for<br>the full text of the H<br>statements declared<br>above. | ATE [Oral] = 400<br>mg/kg<br>Skin Sens. 1, H317:<br>C ≥ 0.001%       | [1]     |

There are no additional ingredients present which, within the current knowledge of the supplier and in the

concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section. <u>Type</u>

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter  $\leq$  10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

| Eye contact  | : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.   |
|--------------|---|
| Inhalation   | : Remove victim to fresh air and keep at rest in a position comfortable for breathing.<br>If it is suspected that fumes are still present, the rescuer should wear an appropriate<br>mask or self-contained breathing apparatus. If not breathing, if breathing is irregular<br>or if respiratory arrest occurs, provide artificial respiration or oxygen by trained<br>personnel. It may be dangerous to the person providing aid to give mouth-to-mouth<br>resuscitation. Get medical attention. If necessary, call a poison center or physician.<br>If unconscious, place in recovery position and get medical attention immediately.<br>Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or<br>waistband. |
| Skin contact | <ul> <li>Flush contaminated skin with plenty of water. Remove contaminated clothing and<br/>shoes. Get medical attention if symptoms occur. Wash clothing before reuse.<br/>Clean shoes thoroughly before reuse.</li> </ul>   |

## **SECTION 4: First aid measures**

| Ingestion                  | : Wash out mouth with water. Remove dentures if any. If material has been<br>swallowed and the exposed person is conscious, give small quantities of water to<br>drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not<br>induce vomiting unless directed to do so by medical personnel. If vomiting occurs,<br>the head should be kept low so that vomit does not enter the lungs. Get medical<br>attention. If necessary, call a poison center or physician. Never give anything by<br>mouth to an unconscious person. If unconscious, place in recovery position and get<br>medical attention immediately. Maintain an open airway. Loosen tight clothing such<br>as a collar, tie, belt or waistband. |
|----------------------------|---|
| Protection of first-aiders | : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person  |

providing aid to give mouth-to-mouth resuscitation.

#### 4.2 Most important symptoms and effects, both acute and delayed

**Over-exposure signs/symptoms** 

| Eye contact  | : Adverse symptoms may include the following:<br>pain or irritation<br>watering<br>redness  |
|--------------|---|
| Inhalation   | : Adverse symptoms may include the following:<br>nausea or vomiting<br>headache<br>drowsiness/fatigue<br>dizziness/vertigo<br>unconsciousness |
| Skin contact | : No specific data.   |
| Ingestion    | : No specific data.   |

#### 4.3 Indication of any immediate medical attention and special treatment needed

| Notes to physician  | <ul> <li>Treat symptomatically. Contact poison treatment specialist immediately if large<br/>quantities have been ingested or inhaled.</li> </ul> |
|---------------------|---|
| Specific treatments | : No specific treatment.  |

## SECTION 5: Firefighting measures

| 5.1 Extinguishing media<br>Suitable extinguishing<br>media | : Use dry chemical, CO <sub>2</sub> , water spray (fog) or foam. |
|--|--|
| Unsuitable extinguishing media                             | : Do not use water jet.  |

#### 5.2 Special hazards arising from the substance or mixture

Hazards from the : Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with substance or mixture the risk of a subsequent explosion. This material is toxic to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain. **Hazardous combustion** Decomposition products may include the following materials: 5 carbon dioxide products carbon monoxide sulfur oxides phosphorus oxides metal oxide/oxides

#### 5.3 Advice for firefighters

:11/10/2022

## **SECTION 5: Firefighting measures**

|   |   | 6   |
|---|---|---|
| Special protective actions for fire-fighters      | : | Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.                                      |
| Special protective<br>equipment for fire-fighters | : | Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents. |

### **SECTION 6: Accidental release measures**

| 6.1 Personal precautions, pro  | ote | ctive equipment and emergency procedures   |
|--------------------------------|-----|--|
| For non-emergency<br>personnel | :   | No action shall be taken involving any personal risk or without suitable training.<br>Evacuate surrounding areas. Keep unnecessary and unprotected personnel from<br>entering. Do not touch or walk through spilt material. Shut off all ignition sources.<br>No flares, smoking or flames in hazard area. Avoid breathing vapour or mist.<br>Provide adequate ventilation. Wear appropriate respirator when ventilation is<br>inadequate. Put on appropriate personal protective equipment. |
| For emergency responders       | :   | If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".  |
| 6.2 Environmental precautions  | :   | Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains<br>and sewers. Inform the relevant authorities if the product has caused environmental<br>pollution (sewers, waterways, soil or air). Water polluting material. May be harmful<br>to the environment if released in large quantities. Collect spillage.  |

#### 6.3 Methods and material for containment and cleaning up

| Small spill                     | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.   |
|---------------------------------|--|
| Large spill                     | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. |
| 6.4 Reference to other sections | : See Section 1 for emergency contact information.<br>See Section 8 for information on appropriate personal protective equipment.<br>See Section 13 for additional waste treatment information.  |

## **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

| Protective measures : | Put on appropriate personal protective equipment (see Section 8). Do not ingest.<br>Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Avoid<br>release to the environment. Use only with adequate ventilation. Wear appropriate<br>respirator when ventilation is inadequate. Do not enter storage areas and confined<br>spaces unless adequately ventilated. Keep in the original container or an approved<br>alternative made from a compatible material, kept tightly closed when not in use.<br>Store and use away from heat, sparks, open flame or any other ignition source. Use<br>explosion-proof electrical (ventilating, lighting and material handling) equipment.<br>Use only non-sparking tools. Take precautionary measures against electrostatic<br>discharges. Empty containers retain product residue and can be hazardous. Do not<br>reuse container. |
|-----------------------|---|
|-----------------------|---|

## **SECTION 7: Handling and storage**

Advice on general occupational hygiene

: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

#### Seveso Directive - Reporting thresholds

#### Danger criteria

|     | Notification and MAPP threshold | Safety report threshold |
|-----|---------------------------------|-------------------------|
| P5c | 5000 tonne                      | 50000 tonne             |
| E2  | 200 tonne                       | 500 tonne               |

#### 7.3 Specific end use(s)

**Recommendations** 

Not available.Not available.

Industrial sector specific solutions

### **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

#### 8.1 Control parameters

#### **Occupational exposure limits**

| Product/ingredient name                  | Exposure limit values                                       |  |  |  |  |
|--|---|--|--|--|--|
| r-Butyl acetate                          | EU OEL (Europe, 1/2022). Notes: list of indicative          |  |  |  |  |
|  | occupational exposure limit values                          |  |  |  |  |
|  | STEL: 150 ppm 15 minutes.                                   |  |  |  |  |
|  | STEL: 723 mg/m <sup>3</sup> 15 minutes.                     |  |  |  |  |
|  | TWA: 241 mg/m <sup>3</sup> 8 hours.                         |  |  |  |  |
|  | TWA: 50 ppm 8 hours.  |  |  |  |  |
| 2-Methoxy-1-methylethyl acetate          | EU OEL (Europe, 1/2022). Absorbed through skin. Notes: list |  |  |  |  |
|  | of indicative occupational exposure limit values            |  |  |  |  |
|  | TWA: 50 ppm 8 hours.  |  |  |  |  |
|  | TWA: 275 mg/m <sup>3</sup> 8 hours.                         |  |  |  |  |
|  | STEL: 100 ppm 15 minutes.                                   |  |  |  |  |
|  | STEL: 550 mg/m <sup>3</sup> 15 minutes.                     |  |  |  |  |
| sobutyl acetate                          | EU OEL (Europe, 1/2022). Notes: list of indicative          |  |  |  |  |
|  | occupational exposure limit values                          |  |  |  |  |
|  | STEL: 150 ppm 15 minutes.                                   |  |  |  |  |
|  | STEL: 723 mg/m <sup>3</sup> 15 minutes.                     |  |  |  |  |
|  | TWA: 241 mg/m <sup>3</sup> 8 hours.                         |  |  |  |  |
|  | TWA: 50 ppm 8 hours.  |  |  |  |  |
| 2-Butoxyethanol                          | EU OEL (Europe, 1/2022). Absorbed through skin. Notes: list |  |  |  |  |
|  | of indicative occupational exposure limit values            |  |  |  |  |
|  | TWA: 20 ppm 8 hours.  |  |  |  |  |
|  | TWA: 98 mg/m <sup>3</sup> 8 hours.                          |  |  |  |  |
|  | STEL: 50 ppm 15 minutes.                                    |  |  |  |  |
|  | STEL: 246 mg/m <sup>3</sup> 15 minutes.                     |  |  |  |  |
| Methylisobutylketone                     | EU OEL (Europe, 1/2022). Notes: list of indicative          |  |  |  |  |
|  | occupational exposure limit values                          |  |  |  |  |
|  | TWA: 20 ppm 8 hours.  |  |  |  |  |
| te of issue/Date of revision : 06/10/202 | 3 Date of previous issue : 11/10/2022 Version : 1.01 6/19   |  |  |  |  |
|  |   |  |  |  |  |

## **SECTION 8: Exposure controls/personal protection**

TWA: 83 mg/m<sup>3</sup> 8 hours. STEL: 50 ppm 15 minutes. STEL: 208 mg/m<sup>3</sup> 15 minutes.

**Biological exposure indices** 

| Product/ingredient nar                              | Exposure indices   |  |
|---|--|--|
| No exposure indices known.                          |  |  |
| procedures Eu<br>as<br>va<br>ati<br>of<br>(W<br>foi | e should be made to monitoring standards, such as the follo<br>Standard EN 689 (Workplace atmospheres - Guidance for<br>ent of exposure by inhalation to chemical agents for compar<br>d measurement strategy) European Standard EN 14042 (V<br>res - Guide for the application and use of procedures for th<br>re to chemical and biological agents) European Standard E<br>ce atmospheres - General requirements for the performanc<br>easurement of chemical agents) Reference to national guid<br>is for methods for the determination of hazardous substanc | r the<br>rison with limit<br>Workplace<br>le assessment<br>EN 482<br>le of procedures<br>dance |

#### **DNELs/DMELs**

| Product/ingredient name         | Туре | Exposure          | Value                  | Population | Effects  |
|---------------------------------|------|-------------------|------------------------|------------|----------|
| p-Butyl acetate                 | DNEL | Short term Oral   | 2 mg/kg                | General    | Systemic |
|                                 |      |                   | bw/day                 | population |          |
|                                 | DNEL | Long term Oral    | 2 mg/kg                | General    | Systemic |
|                                 |      |                   | bw/day                 | population |          |
|                                 | DNEL | Short term Dermal | 6 mg/kg                | General    | Systemic |
|                                 |      |                   | bw/day                 | population |          |
|                                 | DNEL | Short term Dermal | 11 mg/kg<br>bw/day     | Workers    | Systemic |
|                                 | DNEL | Long term         | 35.7 mg/m <sup>3</sup> | General    | Local    |
|                                 |      | Inhalation        | <u>-</u>               | population |          |
|                                 | DNEL | Short term        | 300 mg/m <sup>3</sup>  | General    | Local    |
|                                 |      | Inhalation        | <b>J</b>               | population |          |
|                                 | DNEL | Short term        | 300 mg/m <sup>3</sup>  | General    | Systemic |
|                                 |      | Inhalation        |                        | population | ,        |
|                                 | DNEL | Long term         | 300 mg/m <sup>3</sup>  | Workers    | Local    |
|                                 |      | Inhalation        |                        |            |          |
|                                 | DNEL | Short term        | 600 mg/m <sup>3</sup>  | Workers    | Local    |
|                                 |      | Inhalation        | 0                      |            |          |
|                                 | DNEL | Short term        | 600 mg/m <sup>3</sup>  | Workers    | Systemic |
|                                 |      | Inhalation        | Ũ                      |            |          |
|                                 | DNEL | Long term Dermal  | 3.4 mg/kg              | General    | Systemic |
|                                 |      | Ŭ                 | bw/day                 | population |          |
|                                 | DNEL | Long term Dermal  | 7 mg/kg<br>bw/day      | Workers    | Systemic |
|                                 | DNEL | Long term         | 12 mg/m <sup>3</sup>   | General    | Systemic |
|                                 |      | Inhalation        | 0                      | population | -        |
|                                 | DNEL | Long term         | 48 mg/m <sup>3</sup>   | Workers    | Systemic |
|                                 |      | Inhalation        | -                      |            |          |
| 2-Methoxy-1-methylethyl acetate | DNEL | Long term         | 33 mg/m <sup>3</sup>   | General    | Local    |
|                                 |      | Inhalation        |                        | population |          |
|                                 | DNEL | Long term         | 33 mg/m³               | General    | Systemic |
|                                 |      | Inhalation        |                        | population |          |
|                                 | DNEL | Long term Oral    | 36 mg/kg               | General    | Systemic |
|                                 |      |                   | bw/day                 | population |          |
|                                 | DNEL | Long term         | 275 mg/m <sup>3</sup>  | Workers    | Systemic |
|                                 |      | Inhalation        |                        |            |          |
|                                 | DNEL | Long term Dermal  | 320 mg/kg              | General    | Systemic |
|                                 |      |                   | bw/day                 | population |          |
|                                 | DNEL | Short term        | 550 mg/m <sup>3</sup>  | Workers    | Local    |
|                                 |      | Inhalation        |                        |            |          |
|                                 | DNEL | Long term Dermal  | 796 mg/kg<br>bw/day    | Workers    | Systemic |
| Trizinc bis(orthophosphate)     | DNEL | Long term Oral    | 0.83 mg/               | General    | Systemic |
| ,                               | 1    | -                 | -                      |            |          |

TEKNODUR COMBI 3440-05 - All variants

|                      |       |                                       | kg bw/day                       | population            |             |
|----------------------|-------|---------------------------------------|---------------------------------|-----------------------|-------------|
|                      | DNEL  | Long term                             | 2.5 mg/m³                       | General               | Systemic    |
|                      | DNE   | Inhalation                            | <b>5</b>                        | population            | 0           |
|                      | DNEL  | Long term                             | 5 mg/m³                         | Workers               | Systemic    |
|                      |       | Inhalation                            |                                 | Comorol               | C) retermin |
|                      | DNEL  | Long term Dermal                      | 83 mg/kg<br>bw/day              | General population    | Systemic    |
|                      | DNEL  | Long term Dermal                      | 83 mg/kg                        | Workers               | Systemic    |
| Isobutyl acetate     | DNEL  | Short term Oral                       | bw/day<br>5 mg/kg               | General               | Systemic    |
|                      | DNEL  | Long term Oral                        | bw/day<br>5 mg/kg               | population<br>General | Systemic    |
|                      | DNEL  | Short term Dermal                     | bw/day<br>5 mg/kg               | population<br>General | Systemic    |
|                      | DNEL  | Long term Dermal                      | bw/day<br>5 mg/kg               | population<br>General | Systemic    |
|                      | DNEL  | Short term Dermal                     | bw/day<br>10 mg/kg              | population<br>Workers | Systemic    |
|                      | DNEL  | Long term Dermal                      | bw/day<br>10 mg/kg              | Workers               | Systemic    |
|                      | DNEL  | Long term                             | bw/day<br>35.7 mg/m³            |                       | Local       |
|                      |       | Inhalation                            | 55.7 mg/m                       | population            | Looal       |
|                      | DNEL  | Long term                             | 35.7 mg/m <sup>3</sup>          | General               | Systemic    |
|                      |       | Inhalation                            | Ũ                               | population            | ,           |
|                      | DNEL  | Short term                            | 300 mg/m <sup>3</sup>           | General               | Local       |
|                      |       | Inhalation                            |                                 | population            |             |
|                      | DNEL  | Short term                            | 300 mg/m <sup>3</sup>           | General               | Systemic    |
|                      | DNEL  | Inhalation                            | $200 m g/m^{3}$                 | population<br>Workers |             |
|                      | DINEL | Long term<br>Inhalation               | 300 mg/m <sup>3</sup>           | vorkers               | Local       |
|                      | DNEL  | Long term<br>Inhalation               | 300 mg/m <sup>3</sup>           | Workers               | Systemic    |
|                      | DNEL  | Short term                            | 600 mg/m³                       | Workers               | Local       |
|                      | DNEL  | Inhalation<br>Short term              | 600 mg/m³                       | Workers               | Systemic    |
| 2-Butoxyethanol      | DNEL  | Inhalation<br>Long term Oral          | 6.3 mg/kg                       | General               | Systemic    |
|                      | DNEL  | Short term Oral                       | bw/day<br>26.7 mg/              | population<br>General | Systemic    |
|                      | DNEL  | Long term                             | kg bw/day<br>59 mg/m³           | population<br>General | Systemic    |
|                      | DNEL  | Inhalation<br>Long term               | 98 mg/m³                        | population<br>Workers | Systemic    |
|                      |       | Inhalation                            | 117                             | Constal               |             |
|                      | DNEL  | Short term<br>Inhalation              | 147 mg/m³                       | General population    | Local       |
|                      | DNEL  | Short term<br>Inhalation              | 246 mg/m³                       | Workers               | Local       |
|                      | DNEL  | Short term<br>Inhalation              | 426 mg/m <sup>3</sup>           | General<br>population | Systemic    |
|                      | DNEL  | Short term<br>Inhalation              | 1091 mg/<br>m³                  | Workers               | Systemic    |
| Methylisobutylketone | DNEL  | Long term Oral                        | 4.2 mg/kg                       | General               | Systemic    |
|                      | DNEL  | Long term Dermal                      | bw/day<br>4.2 mg/kg             | population<br>General | Systemic    |
|                      | DNEL  | Long term Dermal                      | bw/day<br>11.8 mg/<br>kg bw/day | population<br>Workers | Systemic    |
|                      | DNEL  | Long term<br>Inhalation               | 14.7 mg/m <sup>3</sup>          | General               | Local       |
|                      | DNEL  | Long term                             | 14.7 mg/m³                      | population<br>General | Systemic    |
|                      | DNEL  | Inhalation<br>Long term<br>Inhalation | 83 mg/m³                        | population<br>Workers | Local       |
|                      |       |                                       |                                 |                       |             |

TEKNODUR COMBI 3440-05 - All variants

| ECTION 8: Exposure     | •     | -                 |  |            |           |
|------------------------|-------|-------------------|--|------------|-----------|
|                        | DNEL  | Long term         | 83 mg/m³                                 | Workers    | Systemic  |
|                        | DNE   | Inhalation        | 455.0                                    | 0          | 1         |
|                        | DNEL  | Short term        | 155.2 mg/                                | General    | Local     |
|                        |       | Inhalation        | m <sup>3</sup>                           | population |           |
|                        | DNEL  | Short term        | 155.2 mg/                                | General    | Systemic  |
|                        |       | Inhalation        | m³                                       | population |           |
|                        | DNEL  | Short term        | 208 mg/m <sup>3</sup>                    | Workers    | Local     |
|                        |       | Inhalation        |  |            |           |
|                        | DNEL  | Short term        | 208 mg/m <sup>3</sup>                    | Workers    | Systemic  |
|                        |       | Inhalation        |  |            |           |
| propylidynetrimethanol | DNEL  | Long term Oral    | 0.34 mg/                                 | General    | Systemic  |
|                        |       |                   | kg bw/day                                | population |           |
|                        | DNEL  | Long term Dermal  | 0.34 mg/                                 | General    | Systemic  |
|                        |       |                   | kg bw/day                                | population |           |
|                        | DNEL  | Long term         | 0.58 mg/m <sup>3</sup>                   | General    | Systemic  |
|                        |       | Inhalation        |  | population |           |
|                        | DNEL  | Long term Dermal  | 0.94 mg/                                 | Workers    | Systemic  |
|                        |       |                   | kg bw/day                                |            |           |
|                        | DNEL  | Long term         | 3.3 mg/m <sup>3</sup>                    | Workers    | Systemic  |
|                        |       | Inhalation        | J. J |            |           |
| Valeic anhydride       | DNEL  | Long term         | 0.081 mg/                                | Workers    | Local     |
| 2                      |       | Inhalation        | m³                                       |            |           |
|                        | DNEL  | Long term         | 0.081 mg/                                | Workers    | Systemic  |
|                        |       | Inhalation        | m³                                       |            |           |
|                        | DNEL  | Short term        | 0.2 mg/m <sup>3</sup>                    | Workers    | Local     |
|                        |       | Inhalation        | - <b>J</b>                               |            |           |
|                        | DNEL  | Short term        | 0.2 mg/m <sup>3</sup>                    | Workers    | Systemic  |
|                        |       | Inhalation        | - <b>J</b>                               |            | ,         |
|                        | DNEL  | Long term         | 0.05 mg/m <sup>3</sup>                   | General    | Systemic  |
|                        |       | Inhalation        | 0  | population | ,         |
|                        | DNEL  | Long term Oral    | 0.06 mg/                                 | General    | Systemic  |
|                        |       | 5                 | kg bw/day                                | population | ,         |
|                        | DNEL  | Long term         | 0.08 mg/m <sup>3</sup>                   | General    | Local     |
|                        |       | Inhalation        | <u>-</u>                                 | population |           |
|                        | DNEL  | Short term Oral   | 0.1 mg/kg                                | General    | Systemic  |
|                        |       |                   | bw/day                                   | population |           |
|                        | DNEI  | Short term Dermal | 0.1 mg/kg                                | General    | Systemic  |
|                        | DILLE | enert term Derma  | bw/day                                   | population | Cyclonno  |
|                        | DNEL  | Long term Dermal  | 0.1 mg/kg                                | General    | Systemic  |
|                        |       | Long torm Dorma   | bw/day                                   | population | Cystonio  |
|                        | DNEL  | Short term Dermal | 0.2 mg/kg                                | Workers    | Systemic  |
|                        |       |                   | bw/day                                   |            |           |
|                        | DNEL  | Long term Dermal  | 0.2 mg/kg                                | Workers    | Systemic  |
|                        |       |                   | bw/day                                   | WOINCIS    | Cysternic |

#### **PNECs**

No PNECs available

| 8.2 Exposure controls            |  |  |
|----------------------------------|--|--|
| Appropriate engineering controls | Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.                   |  |
| Individual protection measured   |  |  |
| Hygiene measures                 | Wash hands, forearms and face thoroughly after handling chemical products,<br>before eating, smoking and using the lavatory and at the end of the working period<br>Appropriate techniques should be used to remove potentially contaminated clothin<br>Wash contaminated clothing before reusing. Ensure that eyewash stations and<br>safety showers are close to the workstation location. |  |

: 06/10/2023 Date of previous issue

: 11/10/2022

## SECTION 8: Exposure controls/personal protection

| Eye/face protection    | : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.  |
|------------------------|---|
| Skin protection        |   |
| Hand protection        | : Chemical-resistant, impervious gloves complying with an approved standard should<br>be worn at all times when handling chemical products if a risk assessment indicates<br>this is necessary. Considering the parameters specified by the glove manufacturer,<br>check during use that the gloves are still retaining their protective properties. It<br>should be noted that the time to breakthrough for any glove material may be<br>different for different glove manufacturers. In the case of mixtures, consisting of<br>several substances, the protection time of the gloves cannot be accurately<br>estimated. |
|                        | Recommendations : Wear suitable gloves tested to EN374.   |
|                        | < 1 hour (breakthrough time): Nitrile gloves. thickness > 0.3 mm  |
|                        | 1 - 4 hours (breakthrough time): polyvinyl alcohol (PVA) thickness > 0.3 mm or $4H$ / Silver Shield® gloves.  |
|                        | > 8 hours (breakthrough time): Viton® thickness > 0.3 mm gloves   |
|                        | Wash hands before breaks and immediately after handling the product.  |
| Body protection        | : Personal protective equipment for the body should be selected based on the task<br>being performed and the risks involved and should be approved by a specialist<br>before handling this product. When there is a risk of ignition from static electricity,<br>wear anti-static protective clothing. For the greatest protection from static<br>discharges, clothing should include anti-static overalls, boots and gloves. Refer to<br>European Standard EN 1149 for further information on material and design<br>requirements and test methods.  |
| Other skin protection  | <ul> <li>Appropriate footwear and any additional skin protection measures should be<br/>selected based on the task being performed and the risks involved and should be<br/>approved by a specialist before handling this product.</li> </ul>   |
| Respiratory protection | <ul> <li>Based on the hazard and potential for exposure, select a respirator that meets the<br/>appropriate standard or certification. Respirators must be used according to a<br/>respiratory protection program to ensure proper fitting, training, and other important<br/>aspects of use.</li> <li>Filter type: A</li> </ul>  |
|                        | Filter type (spray application): A P  |
| Environmental exposure | : Emissions from ventilation or work process equipment should be checked to   |
| controls               | ensure they comply with the requirements of environmental protection legislation.<br>In some cases, fume scrubbers, filters or engineering modifications to the process<br>equipment will be necessary to reduce emissions to acceptable levels.  |

## **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

| Appearance                                 |                  |                |                 |           |                     |  |  |
|--|------------------|----------------|-----------------|-----------|---------------------|--|--|
| Physical state                             | : Liquid.        | : Liquid.      |                 |           |                     |  |  |
| Colour                                     | : Various        |                |                 |           |                     |  |  |
| Odour                                      | : Slight         |                |                 |           |                     |  |  |
| Odour threshold                            | : Not available. |                |                 |           |                     |  |  |
| Melting point/freezing point               | : Not available. |                |                 |           |                     |  |  |
| Initial boiling point and<br>boiling range | :                |                |                 |           |                     |  |  |
| Ingredient name                            |                  | °C             | °F              | Method    |                     |  |  |
| sobutyl acetate                            |                  | 117            | 242.6           | OECD 103  |                     |  |  |
| n-Butyl acetate                            |                  | 126            | 258.8           | OECD 103  |                     |  |  |
| Flammability                               | : Not av         | ailable.       | ł               | ł         |                     |  |  |
| Date of issue/Date of revision             | : 06/10/2023     | B Date of prev | rious issue : 1 | 1/10/2022 | ersion : 1.01 10/19 |  |  |

TEKNODUR COMBI 3440-05 - All variants

Version : 1.01 10/19 Label No :50885

| <b>SECTION 9: Physical an</b>              | nd                        | chem                         | nical p  | roperti | es    |  |           |  |  |
|--|---------------------------|------------------------------|----------|---------|-------|--|-----------|--|--|
| Lower and upper explosion limit            | :                         | : Lower: 1.4%<br>Upper: 7.6% |          |         |       |  |           |  |  |
| Flash point                                | : Closed cup: 25°C (77°F) |                              |          |         |       |  |           |  |  |
| Auto-ignition temperature                  | :                         |                              |          |         |       |  |           |  |  |
| Ingredient name                            |                           |                              | °C       |         | °F    |  | Method    |  |  |
| P-Methoxy-1-methylethyl acetate            |                           |                              | 333      |         | 631.4 |  | DIN 51794 |  |  |
| n-Butyl acetate                            |                           |                              | 415      |         | 779   |  | EU A.15   |  |  |
| Decomposition temperature                  | :                         | Not ava                      | ilable.  |         |       |  |           |  |  |
| рН   | :                         | Not app                      | licable. |         |       |  |           |  |  |
| Viscosity                                  | :                         | Not ava                      | ilable.  |         |       |  |           |  |  |
| Solubility(ies)                            | :                         |                              |          |         |       |  |           |  |  |
| Not available.                             |                           |                              |          |         |       |  |           |  |  |
| Solubility in water                        | :                         | Not ava                      | ilable.  |         |       |  |           |  |  |
| Partition coefficient: n-octanol/<br>water | :                         | Not app                      | licable. |         |       |  |           |  |  |
| Vapour pressure                            | :                         |                              |          |         |       |  |           |  |  |

#### Vapour pressure

|                          | Vapour Pressure at 20°C |             |                | Vapour pressure at 50°C |     |        |  |
|--------------------------|-------------------------|-------------|----------------|-------------------------|-----|--------|--|
| Ingredient name          | mm Hg                   | kPa         | Method         | mm Hg                   | kPa | Method |  |
| sobutyl acetate          | 15.75134                | 2.1         | DIN EN 13016-2 |                         |     |        |  |
| n-Butyl acetate          | 11.25096                | 1.5         | DIN EN 13016-2 |                         |     |        |  |
| Relative density         | : Not                   | available.  | •              |                         |     |        |  |
| Density                  | : 1.5                   | g/cm³       |                |                         |     |        |  |
| Vapour density           | : Not                   | available.  |                |                         |     |        |  |
| Explosive properties     | : Not                   | available.  |                |                         |     |        |  |
| Oxidising properties     | : Not                   | available.  |                |                         |     |        |  |
| Particle characteristics |                         |             |                |                         |     |        |  |
| Median particle size     | : Not                   | applicable. |                |                         |     |        |  |
|                          |                         |             |                |                         |     |        |  |

## SECTION 10: Stability and reactivity

| 10.1 Reactivity                            | : No specific test data related to reactivity available for this product or its ingredients.  |
|--|---|
| 10.2 Chemical stability                    | : The product is stable.  |
| 10.3 Possibility of<br>hazardous reactions | : Under normal conditions of storage and use, hazardous reactions will not occur.   |
| 10.4 Conditions to avoid                   | : Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition. |
| 10.5 Incompatible materials                | : Reactive or incompatible with the following materials: oxidising materials  |
| 10.6 Hazardous<br>decomposition products   | : Under normal conditions of storage and use, hazardous decomposition products should not be produced.  |

## **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

#### Acute toxicity

| Product/ingredient name         | Result                 | Species | Dose         | Exposure |
|---------------------------------|------------------------|---------|--------------|----------|
| n-Butyl acetate                 | LC50 Inhalation Vapour | Rat     | 0.74 mg/l    | 4 hours  |
| -                               | LD50 Dermal            | Rabbit  | 14112 mg/kg  | -        |
|                                 | LD50 Oral              | Rat     | 10760 mg/kg  | -        |
| 2-Methoxy-1-methylethyl acetate | LD50 Dermal            | Rabbit  | >5 g/kg      | -        |
|                                 | LD50 Oral              | Rat     | 8532 mg/kg   | -        |
| Isobutyl acetate                | LD50 Dermal            | Rabbit  | >17400 mg/kg | -        |
| -                               | LD50 Oral              | Rat     | 13400 mg/kg  | -        |
| Methylisobutylketone            | LD50 Oral              | Rat     | 2080 mg/kg   | -        |
| propylidynetrimethanol          | LD50 Oral              | Rat     | 14000 mg/kg  | -        |
| Maleic anhydride                | LD50 Dermal            | Rabbit  | 2620 mg/kg   | -        |
| -                               | LD50 Oral              | Rat     | 400 mg/kg    | -        |

#### Acute toxicity estimates

| Route              | ATE value   |
|--------------------|-------------|
| halation (vapours) | 314.91 mg/l |

#### Irritation/Corrosion

| Product/ingredient name  | Result                         | Species           | Score      | Exposure     | Observation |
|--------------------------|--------------------------------|-------------------|------------|--------------|-------------|
| <b>ti</b> tanium dioxide | Skin - Mild irritant           | Human             | -          | 72 hours 300 | -           |
|                          |                                |                   |            | ug l         |             |
| n-Butyl acetate          | Eyes - Moderate irritant       | Rabbit            | -          | 100 mg       | -           |
|                          | Skin - Moderate irritant       | Rabbit            | -          | 24 hours 500 | -           |
|                          |                                |                   |            | mg           |             |
| Isobutyl acetate         | Eyes - Moderate irritant       | Rabbit            | -          | 24 hours 500 | -           |
|                          |                                |                   |            | mg           |             |
|                          | Skin - Mild irritant           | Rabbit            | -          | 500 mg       | -           |
|                          | Skin - Moderate irritant       | Rabbit            | -          | 24 hours 500 | -           |
|                          |                                |                   |            | mg           |             |
| 2-Butoxyethanol          | Eyes - Moderate irritant       | Rabbit            | -          | 24 hours 100 | -           |
|                          |                                | <b>D</b> 11 11    |            | mg           |             |
|                          | Eyes - Severe irritant         | Rabbit            | -          | 100 mg       | -           |
|                          | Skin - Mild irritant           | Rabbit            | -          | 500 mg       | -           |
| Methylisobutylketone     | Eyes - Moderate irritant       | Rabbit            | -          | 24 hours 100 | -           |
|                          |                                |                   |            | uL           |             |
|                          | Eyes - Severe irritant         | Rabbit            | -          | 40 mg        | -           |
|                          | Skin - Mild irritant           | Rabbit            | -          | 24 hours 500 | -           |
|                          |                                |                   |            | mg           |             |
| Maleic anhydride         | Eyes - Severe irritant         | Rabbit            | -          | 1 %          | -           |
| Conclusion/Summary       | : Based on available data, the | classification cr | iteria are | not met.     |             |
| Sensitisation            |                                |                   |            |              |             |
| 201101110111             |                                |                   |            |              |             |

| Conclusion/Summary | 4 | Based on available data, | th | ne classification criteria are not met. |
|--------------------|---|--------------------------|----|---|
|                    |   |                          |    |   |

## Mutagenicity

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

#### **Carcinogenicity**

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

| <b>Conclusion/Summary</b> | : Based on available data, the classification criteria are not met. |  |
|---------------------------|---|--|
| Reproductive toxicity     |   |  |
| <b>Conclusion/Summary</b> | : Based on available data, the classification criteria are not met. |  |
| <u>Teratogenicity</u>     |   |  |
| <b>Conclusion/Summary</b> | : Based on available data, the classification criteria are not met. |  |
| Specific target organ tox | <u>icity (single exposure)</u>                                      |  |

| Date of issue/Date of revision | :06/10/2023  | Date of previous issue | : 11/10/2022 | Version : 1.01 12/19 |
|--------------------------------|--------------|------------------------|--------------|----------------------|
| TEKNODUR COMBI 3440-05 - J     | All variants |                        |              | Label No :50885      |

## **SECTION 11: Toxicological information**

| •  |  |                   |  |
|--|--|-------------------|--|
| Product/ingredient name  | Category   | Route of exposure | Target organs  |
| n-Butyl acetate<br>2-Methoxy-1-methylethyl acetate<br>Isobutyl acetate<br>Methylisobutylketone | Category 3<br>Category 3<br>Category 3<br>Category 3 | -<br>-<br>-       | Narcotic effects<br>Narcotic effects<br>Narcotic effects<br>Narcotic effects |

#### Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category   | Route of exposure | Target organs      |
|-------------------------|------------|-------------------|--------------------|
| Maleic anhydride        | Category 1 | inhalation        | respiratory system |

#### **Aspiration hazard**

Not available.

| TEKNODUR COMBI 3440-05 -             | Δ         |  |
|--------------------------------------|-----------|--|
| Date of issue/Date of revision       | -         | : 06/10/2023 Date of previous issue : 11/10/2022 Version : 1.01 13/1   |
| Reproductive toxicity                | ÷         | No known significant effects or critical hazards.  |
| Mutagenicity                         | ÷         | No known significant effects or critical hazards.  |
| Carcinogenicity                      | 1         | No known significant effects or critical hazards.  |
| General                              | 1         | No known significant effects or critical hazards.  |
| Conclusion/Summary                   |           | Not available.   |
| Not available.                       |           | -  |
| Potential chronic health effe        | - 1       |  |
| effects<br>Potential delayed effects |           | Not available.   |
| Potential immediate                  | :         | Not available.   |
| Long term exposure                   |           |  |
| Potential delayed effects            | :         | Not available.   |
| Potential immediate<br>effects       | ;         | Not available.   |
| <u>Short term exposure</u>           | <u>ts</u> | as well as chronic effects from short and long-term exposure   |
| -                                    |           |  |
| Ingestion                            |           | No specific data.  |
| Skin contact                         |           | unconsciousness<br>No specific data.   |
|                                      |           | headache<br>drowsiness/fatigue<br>dizziness/vertigo  |
| Inhalation                           | ;         | Adverse symptoms may include the following:<br>nausea or vomiting  |
| Eye contact                          |           | Adverse symptoms may include the following:<br>pain or irritation<br>watering<br>redness                     |
|                                      |           | cal, chemical and toxicological characteristics  |
| -                                    |           |  |
| Skin contact<br>Ingestion            |           | No known significant effects or critical hazards.<br>Can cause central nervous system (CNS) depression.      |
|                                      |           | dizziness.   |
| Eye contact<br>Inhalation            |           | Causes serious eye irritation.<br>Can cause central nervous system (CNS) depression. May cause drowsiness or |
| Potential acute health effects       |           |  |
| of exposure                          |           |  |
| Information on likely routes         | :         | Not available.   |

TEKNODUR COMBI 3440-05 - All variants

## **SECTION 11: Toxicological information**

#### 11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

| Product/ingredient name     | Result   | Species  | Exposure                         |
|-----------------------------|--|--|----------------------------------|
| utanium dioxide             | Acute LC50 3 mg/l Fresh water  | Crustaceans - Ceriodaphnia<br>dubia - Neonate  | 48 hours                         |
|                             | Acute LC50 6.5 mg/l Fresh water  | Daphnia - <i>Daphnia pulex -</i><br>Neonate  | 48 hours                         |
|                             | Acute LC50 >1000000 μg/l Marine<br>water   | Fish - Fundulus heteroclitus   | 96 hours                         |
| n-Butyl acetate             | Acute LC50 32 mg/l Marine water  | Crustaceans - Artemia salina   | 48 hours                         |
| -                           | Acute LC50 18000 µg/l Fresh water  | Fish - Pimephales promelas   | 96 hours                         |
| Trizinc bis(orthophosphate) | Acute EC50 0.32 mg/l   | Algae - Selenastrum<br>capricornutum   | 72 hours                         |
|                             | Acute EC50 0.96 mg/l   | Crustaceans - Ceriodaphnia<br>dubia  | 48 hours                         |
| 2-Butoxyethanol             | Acute EC50 >1000 mg/l Fresh water<br>Acute LC50 800000 μg/l Marine water<br>Acute LC50 1250000 μg/l Marine water | Daphnia - <i>Daphnia magna</i><br>Crustaceans - <i>Crangon crangon</i><br>Fish - <i>Menidia beryllina</i>            | 48 hours<br>48 hours<br>96 hours |
| Methylisobutylketone        | Acute LC50 505000 µg/l Fresh water<br>Chronic NOEC 78 mg/l Fresh water<br>Chronic NOEC 168 mg/l Fresh water      | Fish - <i>Pimephales promelas</i><br>Daphnia - <i>Daphnia magna</i><br>Fish - <i>Pimephales promelas</i> -<br>Embryo | 96 hours<br>21 days<br>33 days   |
| propylidynetrimethanol      | Acute EC50 13000000 μg/l Fresh water<br>Acute LC50 14400000 μg/l Marine<br>water                                 |  | 48 hours<br>96 hours             |
| Maleic anhydride            | Acute LC50 230000 μg/l Fresh water   | Fish - <i>Gambusia affinis</i> - Adult   | 96 hours                         |
| Conclusion/Summary          | : Toxic to aquatic life with long lasting e  |  | 1                                |

#### 12.2 Persistence and degradability

**Conclusion/Summary** : This product has not been tested for biodegradation.

#### 12.3 Bioaccumulative potential

| Product/ingredient name     | LogPow | BCF   | Potential |
|-----------------------------|--------|-------|-----------|
| <b>p</b> -Butyl acetate     | 2.3    | -     | Low       |
| 2-Methoxy-1-methylethyl     | 1.2    | -     | Low       |
| acetate                     |        |       |           |
| Trizinc bis(orthophosphate) | -      | 60960 | High      |
| Isobutyl acetate            | 2.3    | -     | Low       |
| 2-Butoxyethanol             | 0.81   | -     | Low       |
| Methylisobutylketone        | 1.9    | -     | Low       |
| propylidynetrimethanol      | -0.47  | <1    | Low       |
| Maleic anhydride            | -2.78  | -     | Low       |

#### 12.4 Mobility in soil

| Soil/water partition coefficient (Koc) | : Not available. |
|--|------------------|
| Mobility                               | : Not available. |

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

#### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

#### **SECTION 13: Disposal considerations**

| 13.1 Waste treatment meth         | ods   |
|-----------------------------------|---|
| Product                           |   |
| Methods of disposal               | : The generation of waste should be avoided or minimised wherever possible.<br>Disposal of this product, solutions and any by-products should at all times comply<br>with the requirements of environmental protection and waste disposal legislation and<br>any regional local authority requirements. Dispose of surplus and non-recyclable<br>products via a licensed waste disposal contractor. Waste should not be disposed of<br>untreated to the sewer unless fully compliant with the requirements of all authorities<br>with jurisdiction. |
| Hazardous waste                   | : The classification of the product may meet the criteria for a hazardous waste.  |
| European waste<br>catalogue (EWC) | : 080111*   |
| Packaging                         |   |
| Methods of disposal               | : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.  |
| Special precautions               | : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.         |

## **SECTION 14: Transport information**

|                                    | ADR/RID | ADN    | IMDG   | ΙΑΤΑ  |
|------------------------------------|---------|--------|--------|---|
| 14.1 UN number<br>or ID number     | UN1263  | UN1263 | UN1263 | UN1263  |
| 14.2 UN proper<br>shipping name    | PAINT   | PAINT  | PAINT  | PAINT   |
| 14.3 Transport<br>hazard class(es) | 3       |        |        | 3   |
| 14.4 Packing<br>group              | 111     | Ш      | Ш      | Ш   |
| 14.5<br>Environmental<br>hazards   | Yes.    | Yes.   | Yes.   | Yes. The<br>environmentally<br>hazardous substance<br>mark is not required. |

**ADR/RID** 

: The environmentally hazardous substance mark is not required when transported in sizes of  $\leq 5 \text{ L}$  or  $\leq 5 \text{ kg}$ .

Tunnel code (D/E)

| SECTION 14: Transport information                                  |   |  |
|--|---|--|
| ADN  | : The environmentally hazardous substance mark is not required when transported in sizes of ≤5 L or ≤5 kg.  |  |
| IMDG   | : The marine pollutant mark is not required when transported in sizes of $\leq$ 5 L or $\leq$ 5 kg.   |  |
| ΙΑΤΑ   | : The environmentally hazardous substance mark may appear if required by other transportation regulations.  |  |
| 14.6 Special precautions for user                                  | : <b>Transport within user's premises:</b> always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage. |  |
| 14.7 Maritime transport in<br>bulk according to IMO<br>instruments | : Not relevant/applicable due to nature of the product.   |  |
| SECTION 15: Regulatory information                                 |   |  |

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>EU Regulation (EC) No. 1907/2006 (REACH)</u>

#### Annex XIV - List of substances subject to authorisation

#### Annex XIV

None of the components are listed.

#### Substances of very high concern

None of the components are listed.

# Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

| Product/ingredient name  | %             | Designation [Usage] |  |
|--|---------------|---------------------|--|
| FEKNODUR COMBI 3440-05   | ≥90           | 3                   |  |
| Labelling :  |               | •                   |  |
| Other EU regulations   |               |                     |  |
| Industrial emissions : Not listed<br>(integrated pollution<br>prevention and control) -<br>Air   |               |                     |  |
| Industrial emissions : Not listed<br>(integrated pollution<br>prevention and control) -<br>Water |               |                     |  |
| Explosive precursors : Not applied   | able.         |                     |  |
| Ozone depleting substances (1005/200   | <u>9/EU)</u>  |                     |  |
| Not listed.  |               |                     |  |
| Prior Informed Consent (PIC) (649/2012   | <u>/EU)</u>   |                     |  |
| Not listed.  |               |                     |  |
| Persistent Organic Pollutants<br>Not listed.   |               |                     |  |
| Seveso Directive   |               |                     |  |
| This product is controlled under the Seves   | so Directive. |                     |  |
| Danger criteria  |               |                     |  |
| Category   |               |                     |  |
| P5c  |               |                     |  |
| E2   |               |                     |  |

#### International regulations

Date of issue/Date of revision : 06/10/2 TEKNODUR COMBI 3440-05 - All variants

: 06/10/2023 Date of previous issue

:11/10/2022

## **SECTION 15: Regulatory information**

#### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

#### **Montreal Protocol**

Not listed.

#### Stockholm Convention on Persistent Organic Pollutants

Not listed.

#### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

#### **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

| 1 | 5.2 | Che | mical | safety |
|---|-----|-----|-------|--------|
| a | 922 | ssm | ent   |        |

: This product contains substances for which Chemical Safety Assessments are still required.

## **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

| Abbreviations and acronyms | <ul> <li>ATE = Acute Toxicity Estimate<br/>CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.<br/>1272/2008]<br/>DMEL = Derived Minimal Effect Level<br/>DNEL = Derived No Effect Level<br/>EUH statement = CLP-specific Hazard statement<br/>N/A = Not available</li> <li>PBT = Persistent, Bioaccumulative and Toxic</li> <li>PNEC = Predicted No Effect Concentration</li> <li>RRN = REACH Registration Number</li> <li>SGG = Segregation Group</li> </ul> |
|----------------------------|--|
|                            | SGG = Segregation Group<br>vPvB = Very Persistent and Very Bioaccumulative   |

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification          | Justification         |
|-------------------------|-----------------------|
| Flam. Liq. 3, H226      | On basis of test data |
| Eye Irrit. 2, H319      | Calculation method    |
| STOT SE 3, H336         | Calculation method    |
| Aquatic Chronic 2, H411 | Calculation method    |

#### Full text of abbreviated H statements

| <b>⊮</b> 225 | Highly flammable liquid and vapour.  |
|--------------|--|
| H226         | Flammable liquid and vapour.   |
| H302         | Harmful if swallowed.  |
| H314         | Causes severe skin burns and eye damage.                                   |
| H315         | Causes skin irritation.  |
| H317         | May cause an allergic skin reaction.                                       |
| H318         | Causes serious eye damage.   |
| H319         | Causes serious eye irritation.   |
| H331         | Toxic if inhaled.  |
| H332         | Harmful if inhaled.  |
| H334         | May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| H336         | May cause drowsiness or dizziness.   |
| H351         | Suspected of causing cancer.   |
| H361fd       | Suspected of damaging fertility. Suspected of damaging the unborn child.   |
| H372         | Causes damage to organs through prolonged or repeated exposure.            |
| H400         | Very toxic to aquatic life.  |
| H410         | Very toxic to aquatic life with long lasting effects.                      |
| H411         | Toxic to aquatic life with long lasting effects.                           |
| EUH066       | Repeated exposure may cause skin dryness or cracking.                      |
| EUH071       | Corrosive to the respiratory tract.  |
|              |  |

#### Full text of classifications [CLP/GHS]

 Date of issue/Date of revision
 : 06/10/2023
 Date of previous issue

 TEKNODUR COMBI 3440-05 - All variants

: 11/10/2022

## **SECTION 16: Other information**

| Acute Tox. 3           | ACUTE TOXICITY - Category 3                                     |
|------------------------|---|
| Acute Tox. 4           | ACUTE TOXICITY - Category 4                                     |
| Aquatic Acute 1        | SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1                  |
| Aquatic Chronic 1      | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1                 |
| Aquatic Chronic 2      | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2                 |
| Carc. 2                | CARCINOGENICITY - Category 2                                    |
| Eye Dam. 1             | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1                  |
| Eye Irrit. 2           | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2                  |
| Flam. Liq. 2           | FLAMMABLE LIQUIDS - Category 2                                  |
| Flam. Liq. 3           | FLAMMABLE LIQUIDS - Category 3                                  |
| Repr. 2                | REPRODUCTIVE TOXICITY - Category 2                              |
| Resp. Sens. 1          | RESPIRATORY SENSITISATION - Category 1                          |
| Skin Corr. 1B          | SKIN CORROSION/IRRITATION - Category 1B                         |
| Skin Irrit. 2          | SKIN CORROSION/IRRITATION - Category 2                          |
| Skin Sens. 1A          | SKIN SENSITISATION - Category 1A                                |
| STOT RE 1              | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 1 |
| STOT SE 3              | SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3   |
| Date of issue/ Date of | : 06/10/2023  |
| revision               |   |
| Date of previous issue | e : 11/10/2022  |
| Version                | : 1.01  |
|                        |   |

#### Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision: 06/10/2023TEKNODUR COMBI 3440-05 - All variants

: 06/10/2023 Date of previous issue

:11/10/2022